Prospective Study of Stereotactic Radiology Using Diffusion-... | Clinical Trial | StuddyBuddy@endsection Prospective Study of Stereotactic Radiology Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05718466

Prospective Study of Stereotactic Radiology Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Conditions: Recurrent or Progressive Glioblastoma

Sex: All
Ages: 18 Years – 100 Years
Phase: PHASE3
Enrollment: 35
Sponsor: Henry Ford Health System

Location: United States

Summary

This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image (DWI) to predict the early tumor progression and treatment response.

Eligibility Criteria

Inclusion Criteria: 1)Histologically proven intracranial glioblastoma multiforme. There must be pathologic or imaging confirmation of tumor progression or regrowth after failure of two previous treatment regimens 2) Patients will be eligible if the original histology was low-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made 3) History and physical exam, including neurologic examination within 4 weeks prior to registration -Exclusion Criteria: Warfarin or LMW heparin patients must have no active bleeding or pathological condition that carries a high risk of bleeding-

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05718466). StuddyBuddy aggregates publicly available trial information.